Melanoma Chemoprevention

黑色素瘤化学预防

• 批准号: 6478671
• 负责人: ROBERT P. DELLAVALLE
• 金额: $ 13.61万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-06-01 至 2007-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6478671
• 关键词: antihypercholesterolemic agent; antineoplastics; cancer prevention; cancer risk; clinical research; computer data analysis; human data; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology; outcomes research; patient oriented research; statistics /biometry

DESCRIPTION (provided by applicant): The incidence of cutaneous malignant melanoma is rising faster than any other cancer in the US. 1 in 74 Americans will develop melanoma, more than 45,000 cases will be diagnosed, and more than 7,500 Americans will die from melanoma this year. Effective prevention of melanoma will not only save lives, but will also decrease the estimated one billion dollars spent annually treating melanoma in the US. There is currently no recognized chemoprevention for melanoma. Two large, randomized, placebo-controlled clinical trials, the VA-HIT Study utilizing gemfibrozil, and the AFCAPS Study utilizing lovastatin, have each reported an association of lipid-lowering medication therapy with statistically significant lower melanoma incidence rates. Lovastatin inhibits melanoma cell growth in tissue culture, and mice Jed lovastatin develop lower lung metastases following tail vein injection with mouse B16 melanoma cells. More recently low concentrations of atorvastatin have been reported to specifically induce apoptosis and inhibit migration of human A375 melanoma cells but not cultured melanocytes. To investigate the unconventional hypothesis that lipid-lowering medications might prevent melanoma, a case-control study will be conducted utilizing Veterans Administration (VA) databases to answer the following question: Do persons who have developed cutaneous malignant melanoma have a history of less lipid-lowering medication exposure than persons who are spared the disease? The answer to this question will help determine whether more expensive and labor intensive randomized prospective clinical trials of potentially teratogenic lipid-lowering medications should be initiated in persons at high risk of developing melanoma. Robert Dellavalle, MD, Ph.D., is an Assistant Professor of Dermatology at the University of Colorado Health Sciences Center and a staff dermatologist at the Denver VA medical center He is committed to a career in academic dermatology and public health. His current career goals are completing a Masters of Science in Public Health and becoming an independent researcher in skin cancer prevention and control.

描述（由申请人提供）：皮肤恶性肿瘤的发生率 黑色素瘤在美国的增长速度比其他任何癌症都要快。 每74个美国人中就有1个 将发展为黑色素瘤，超过45，000例将被诊断，超过1000例将被诊断为黑色素瘤。 今年将有7,500名美国人死于黑素瘤。 有效预防 黑色素瘤不仅可以挽救生命，而且还可以减少估计的死亡率。 在美国每年花费10亿美元治疗黑色素瘤。 目前还没有公认的黑色素瘤化学预防。 两个大的， 随机、安慰剂对照临床试验，VA-HIT研究使用 吉非罗齐和使用洛伐他汀的AFCAPS研究均报告了 降脂药物治疗与统计学相关性 显著降低黑色素瘤发病率。 洛伐他汀抑制黑色素瘤细胞生长 在组织培养中生长，并且小鼠Jed lovastatin发育下肺 尾静脉注射小鼠B16黑色素瘤细胞后转移。 更 最近有报道说，低浓度的阿托伐他汀 诱导人A375黑色素瘤细胞凋亡并抑制其迁移， 培养的黑素细胞。 去调查一个非传统的假设， 降脂药物可能预防黑色素瘤，一项病例对照研究将 利用退伍军人管理局（VA）数据库进行回答 以下问题：患有皮肤恶性肿瘤的人 黑色素瘤的降脂药物暴露史少于 那些没有被感染的人？ 这个问题的答案将有助于 确定是否更昂贵和劳动密集型的随机前瞻性 潜在致畸性降脂药物的临床试验应 在发展为黑色素瘤的高风险人群中启动。 Robert Dellavalle，医学博士，哲学博士，是皮肤科助理教授， 科罗拉多大学健康科学中心的一位皮肤科医生说， 丹佛退伍军人医疗中心他致力于学术皮肤病学的职业生涯 和公共卫生。 他目前的职业目标是完成一个硕士学位， 科学在公共卫生和成为一个独立的研究人员在皮肤癌 防治的攻坚